Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Clinical trial NCT07723703 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07723703
Sponsor: Amphista Therapeutics Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukaemia High Risk Myelodysplastic Syndrome

Start date: 2026-09-01
Primary completion: 2028-12-04
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.